(31-56 h for HCG and~20 min for LH respectively) (Damewood et al., 1989; Saal et al., 1991), whereas HCG FSH is a pituitary glycoprotein essential for follicular growth and LH have a similar affinity for the LH receptor. in females and for spermatogenesis in males (Schaison et al., FSH is used for clinical treatment of both female and male 1993; Out et al., 1999) . FSH belongs, together with LH, infertility. Protocols for the induction of follicular development human chorionic gonadotrophin (HCG), and thyroid-stimulatin women and spermatogenesis in men commonly rely on ing hormone (TSH), to a family of glycoproteins which are multiple injections of FSH preparations (Schaison et al., 1993 ; heterodimers of two subunits, α and β (Moyle et al., 1998) . Out et al., 1999) . The availability of longer-acting FSH would The α-subunits of these hormones are identical, whereas the β-subunits are hormone-specific and therefore determine the thus allow the development of new, more convenient treatment biological specificity. Furthermore, the β-subunit of HCG is regimens. Site-directed mutagenesis and gene transfer techdistinct from the others due to an extension of the Cniques have been used to develop such a novel form of FSH, terminus ('C-terminal peptide' or CTP) with four O-linked which was designated FSH-CTP (Org 36286). This potentially oligosacharides (Boime and Ben-Menahem, 1999). This long-acting recombinant human FSH contains the α-subunit extension of the β-subunit of HCG is believed to contribute of human FSH and a hybrid β-subunit, which is composed of to the prolonged half-life when comparing HCG and LH the β-subunit of human FSH and the CTP part of the β-subunit of HCG.
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*For participant details see Acknowledgements section
Preclinical pharmacokinetic studies in dogs have demon-FSH-CTP were studied in hypogonadotrophic hypogonadal male strated a prolonged half-life (~two times longer) of FSH-CTP 
Materials and methods
FSH-CTP in serum, to study pharmacokinetics or serum testosterone, inhibin-B, and oestradiol concentrations to study the pharmacodynamSubjects ics. The assessment schedule is presented in Table I . A total of 13 hypogonadotrophic hypogonadal male subjects, who fulfilled the inclusion criteria, were enrolled in the present study.
Assessments Main inclusion criteria were: FSH and LH serum concentrations Safety and local tolerance ഛ2 IU/l, age Ͼ30 and Ͻ60 years, body mass index (BMI)
Throughout the entire study, occurrence of (serious) adverse events ഛ32 kg/m 2 , good general physical and mental health, able and willing was monitored. The definition used for an adverse event was: 'any to comply with the protocol, and willing to give written informed untoward medical occurrence in a subject, who is participating in a consent. Main exclusion criteria comprised a history of any disease clinical trial and has been administered a study drug', the definition affecting the immune response, presence of antibodies at screening for a serious adverse event (SAE) was: 'Any untoward medical directed against anti-FSH-CTP or anti-chinese hamster ovary (CHO) occurrence that at any time was life-threatening, required in-patient cell antibodies, testicular or prostate pathology, hypophysectomy hospitalisation or prolonged existing hospitalisation, resulted in within a period of 6 months, hyperprolactinaemia, history of oncologpersistent or significant disability/incapacity, was a congenital ical treatment, and diabetes mellitus. The use of any concomitant anomaly/birth defect, cancer, or an overdose, or resulted in death of medication was not allowed from 14 days prior to the first FSH-CTP the subject'. injection up to and including the post-treatment assessments, except Antibody levels against FSH-CTP were assessed before and during for testosterone and, if required, pituitary hormone replacement the study, using a radio-immunoassay based on the formation of an (other than gonadotrophins), or sporadic use of paracetamol immune complex between the serum-derived specific antibody and (acetaminophen).
[ 125 I]-labelled FSH-CTP. Due to an absence of human antibodies, The mean age (Ϯ SD) of all subjects was 45 (Ϯ 7) years. Mean murine monocolonal antibodies were used as positive controls. height was 176 (Ϯ 7) cm, and the mean weight was 81.7 (Ϯ 13.7)
FSH-CTP was produced by CHO-cells transfected with the genes kg. The mean BMI was 26.4 (Ϯ 3.3) kg/m 2 . For both LH and FSH encoding the α-and β-subunits of human FSH and the CTP-part the median concentrations were 0.5 IU/l. For eight subjects (61.5%), from human chorion gonadotrophin and purified from CHO cell the cause of hypogonadism was hypothalamus-related and for the culture supernatant. Residual CHO cell-derived proteins that are other five subjects the cause was pituitary related. present in minute quantities may cause an immune response in Design of the study subjects treated for infertility with FSH-CTP. To determine the presence of anti-CHO antibodies in human serum after FSH-CTP The study was designed as a phase I, non-blind, multi-centre study in which the safety, pharmacokinetics, and pharmacodynamics of administration, CHO proteins were coated on 96-well microplates Table I . Detailed scheme of hormone assessments Time (h) after injection of FSH-CTP Pre-dose 1 4 6 8 1 0 1 2 1 6 2 4 3 0 3 6 4 8 7 2 9 6 1 4 4 1 9 2 2 4 0 2 8 8 3 3 6
and incubated with human serum samples. When anti-CHO antibodies parametric signed-rank test on t max . All analyses were performed are present in a human serum sample, these antibodies bind to the using SAS Version 6.08 or higher. For pharmacodynamic parameters coated CHO proteins. The bound human anti-CHO antibodies were (testosterone, oestradiol and inhibin-B) only descriptive statistics are detected by goat anti-human immunoglobulin coupled to horse radish presented. peroxidase (GaH Ig HRP).
Routine biochemical and haematological parameters as well as urine analysis were assessed at screening, 24 h after each administration of Results FSH-CTP, and at the post-treatment visit.
As the injection of FSH-CTP was given s.c., the injection site (i.e.
Subject composition
the abdominal wall around the umbilicus) was examined. Monitoring A total of 13 subjects were treated with FSH-CTP. One subject of the injection site was performed 1 and 24 h after each FSH-CTP discontinued the treatment after two injections due to unknown injection by the person who administered the study drug. If possible, reasons. Twelve subjects were exposed to four injections of the same person administered the study drug and monitored the 15 µg FSH-CTP (total 60 µg) with an interval ranging from injection site of a subject throughout the whole study. Redness, 27-39 days. One subject received only two injections with a itching, swelling, pain, and bruising were scored as either none, mild, moderate, or severe reflecting the maximal intensity as experienced 6 weeks interval and subsequently discontinued the study. No by the subject.
concomitant medication known to influence the treatment outcome of subjects was used.
FSH-CTP concentrations
Of the subjects that were included, the hypogonadotrophic For the safety analysis, data from all 13 subjects was used (TMB) substrate. This assay was developed and validated by NV whereas for the pharmacodynamics and pharmacokinetics
Organon (Oss, The Netherlands). Calibration curves for FSH-CTP analysis, data from ten subjects was used. Three subjects were were constructed using 4-parameter-logistic regression. In each anaexcluded from the pharmacodynamics and kinetics analysis lysis series quality control (QC), consisting of human serum, spiked due to measurable concentrations of FSH-CTP before the first with known quantities of FSH-CTP was analysed. The coefficient of dose was administered, which was probably caused by nonvariation (CV) of duplicate determinations did not exceed 20%. The lower limit of quantitation (LLOQ) was 0.079 ng/ml. Selectivity and specific interference of serum proteins (see Materials and specificity of the assay were as follows: selectivity: the results of five methods section for the specificity and selectivity of the assay blank female and six blank male serum samples were below LLOQ. used). In two out of these three subjects, no dose response
One female blank serum sample contained 0.100 ng FSH-CTP/ml.
after FSH-CTP administration was observed at all, in one Specificity: No significant interference could be detected with related subject with a positive read-out at t ϭ 0 h a dose response and endogenous compounds (i.e. α-FSH-CTP, β-FSH-CTP, recFSH, was observed, which peaked at 30 h post administration.
HCG, hTSH, and hLH ϩ hFSH). Only α-FSH-CTP showed some cross-reactivity (~0.5%). All spiked FSH-CTP serum concentrations were within 80-120% limits (12.6-19.0 ng/ml) of the nominal Safety and local tolerance concentration (15.8 ng/ml).
The safety analysis was performed on all subjects that received at least one injection with the investigated compound. No
Measurement of serum hormone concentrations
safety data were excluded from the analysis. In all samples
Measurement of FSH and LH at screening were performed by the analysed, no anti-FSH-CTP or anti-CHO antibodies were laboratory of each participating centre using their standard methods. Inhibin B in human serum was denaturated (using sodium found.
dodecyl sulphate, SDS at 100°C), oxidised (hydrogen peroxide), and
Three subjects (23.1%) experienced a total of five adverse subsequently analysed using an adapted enzyme immunoassay as events (maximum intensity): 'skin disorder' (mild), 'peripreviously described (Robertson et al., 1996) . The detection limit of odontal destruction' (moderate), 'abdominal pain' (mild), and this assay was 15.6 pg/ml and the CV for duplicate determinations twice 'inflicted injury' (mild), none of which was considered did not exceed 20%. Testosterone and oestradiol serum concentrations drug-related.
were determined by Analytisch Biochemisch Laboratorium b.v.
All haematology parameters were within the safety limits (Assen, The Netherlands) using a time-resolved fluoroimmuno assay and no clinically relevant shifts were reported for haemato-(Autodelfia ® ; Delfia; Wallac Oy, Turku, Finland). The lower limit of quantitation of oestradiol concentrations in serum was 13.6 pg/ml logical and biochemical parameters. No clinically significant and for testosterone the detection limit was 0.140 ng/ml. The CV of findings were found at the general medical examination of the quality controls was Ͻ5% for both the oestradiol and testosterone post-treatment assessment.
assays.
The number of subjects with local tolerance symptoms during the entire treatment period and after the first and last
Statistical and analytical methods
injection of FSH-CTP is given in Table II . All reported
The statistical analysis of the pharmacokinetic parameters was carried out using a paired t-test on log-transformed parameters and a nonreactions had a mild intensity.
Pharmacokinetics
respectively, lower after the first injection as compared to the third injection. No statistically significant difference between For two out of ten subjects hardly any or no serum samples the two injections was observed for the time to reach the at all were obtained after the third injection and therefore these maximal concentration. subjects were not included in the analysis. The mean curve shows that serum FSH-CTP concentrations are slightly higher Pharmacodynamics after the third injection than after the first injection (Figure 1) .
Following the first injection with FSH-CTP, a clear rise in Overall, the mean (Ϯ SD) C max was 0.426 (Ϯ 0.116) ng/ml, serum inhibin-B concentrations was observed, which returned mean t max was 45.9 (Ϯ 18.0) h. Because of irregularly shaped to baseline concentration before the next injection was given curves, the elimination half-life (t 1 2 ) and, consequently, AUC 0-ϱ (on average 4 weeks later, Figure 2 ). Similar effects on inhibincould not be estimated for all subjects. For the remaining B serum concentrations were obtained after the third injection subjects, the mean t 1 2 and AUC 0-ϱ were 94.7 (Ϯ 26.2) h and 81.5
with FSH-CTP. The time to reach the maximal concentration (Ϯ 18.8) ng.h/ml respectively. Descriptive statistics of the of inhibin-B (~144 h) was longer than for FSH-CTP (~46 h). FSH-CTP pharmacokinetic parameters are presented in Table III .
Following administration of FSH-CTP hardly any changes were No statistically significant difference between the first and observed in serum testosterone or oestradiol concentrations. third injection was found for all parameters tested, except Descriptive statistics on serum testosterone, oestradiol and for AUC 0-tfix and C max . Back-transformation of the mean inhibin-B concentrations are presented in Table IV and Figure 2 . differences found in the statistical analysis resulted in point estimates of 0.79 and 0.87 for AUC 0-tfix and C max respectively, which means that AUC 0-tfix and C max were 21 and 13% Discussion
This study describes the effects of the first human exposure to FSH-CTP. FSH-CTP is safe and does not lead to detectable oligosacharides (Feng et al., 1995) . It was hypothesised that the extension of the β-subunit could a Injection-site responses could be scored as: redness, itching, swelling, pain, prolong the half-life of FSH-CTP. In agreement herewith, in and bruising and were classified as either none, mild, moderate, or severe.
the current study, the elimination half-life (t 1 2 ) of FSH-CTP in humans was 94.7 Ϯ 26.2 h, which is~2-3 fold longer than the t 1 2 of recombinant human FSH. The elimination half-life of recombinant human FSH has been shown to be~34 h . Mean (Ϯ SD) serum inhibin-B concentration versus time after the first (triangles) and third (squares) injection (depicted is point after the first injection and at least seven after the third injection). At t ϭ 0 h, t ϭ 288h and t ϭ 336h concentrations were the average of at least nine concentrations per time point after the first injection and at least six after the third injection). below the lower limit of quantitation.
Ϯ 5 h in pituitary suppressed females (33 h Ϯ 4 h using serum concentrations by 13 Ϯ 6 h after s.c. injection in females (Voortman et al., 1999) . Puregon ® Pen) (Voortman et al., 1999) . Elimination half-life of recombinant human FSH in a multiple rising dose study in
To determine pharmacodynamic properties of FSH-CTP, serum testosterone, oestradiol and inhibin-B concentrations men with hypogonadotrophic hypogonadism was shown to be 48 Ϯ 5 h (Mannaerts et al., 1996) .
were determined. Inhibin-B has been extensively shown to be the physiologically relevant form of inhibin in men (Anawalt The three-dimensional structure of this new compound is foreign to humans, and therefore possible antigenicity of FSHet al., 1996) . In this study it was shown that the dose of FSH-CTP used caused a rise in inhibin-B concentrations, which CTP was of special consideration. To avoid complications raised by formation of antibodies against native FSH, this returned to baseline concentrations within 4 weeks. This observation is in agreement with recent evidence showing study was performed in hypogonadotrophic hypogonadal male subjects. However, neither anti-FSH-CTP nor anti-CHO antithat treatment of oligozoospermic males with FSH increases inhibin-B plasma concentrations (Foresta et al., 1999) . bodies were found in any analysed samples. Furthermore, measurement of local tolerance demonstrated that s.c. adminisFurthermore, the bioactivity of recombinant FSH in hypogonadotrophic hypogonadal male subjects was also reflected tration of FSH-CTP is well tolerated and no increase in intensity of injection-site responses was observed after repeated by increased inhibin-B levels upon multiple rising doses (Mannaerts et al., 1996) . Hardly any changes were observed exposure to FSH-CTP. Finally, no subjects discontinued due to adverse events. Based on these data, it can be concluded in serum testosterone or oestradiol concentrations after injection of FSH-CTP. In agreement herewith, serum concentrations of that use of FSH-CTP is safe and well tolerated.
LH, testosterone, androstenedione and oestradiol remained Analysis of the mean serum FSH-CTP concentrations unchanged after administration of increasing doses of recomafter the first injection demonstrated that these concentrabinant human FSH to male subjects (Mannaerts et al., 1996) . tions were slightly lower than observed after the third injection.
In conclusion, use of FSH-CTP is safe and does not lead to The discrepancy between the first and third injection with detectable formation of antibodies. This is a promising new FSH-CTP is shown by a statistically significant difference in compound for development of new, more convenient regimens AUC 0-tfix and C max , albeit that the absolute differences are very for the treatment of male and female infertility. small and further research is required to demonstrate the relevance of this observation. When compared with recombinant human FSH, absorption of FSH-CTP appeared to be C max (ng/ml) ϭ maximal concentration at any time; t max (h) ϭ time at which the maximal concentration is reached; t 1 2 (h) ϭ Half-life, AUC 0-ϱ (ng.h/ml) ϭ area under the concentration-time curve from t ϭ 0 h extrapolated to infinity; Cl app (l/h/kg) ϭ apparent clearance defined by clearance divided by absolute bioavailability. 
